文献速递消化系统肿瘤

胰腺癌初治化疗后筛选可切除患者:CA19.9缓解的意义

Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.
PubMed 文献 · Ann Oncol · 2017-01-01

该回顾性研究纳入2002–2016年223例交界可切除或局部晚期胰腺腺癌患者,均接受吉西他滨联合方案初治化疗3–6个月后评估手术。全组中位生存18.3个月,61例接受切除者中位生存30.0个月,显著长于未切除162例的16.5个月(P<0.00001)。CA19.9缓解(下降>50%)者切除后生存优于无缓解者(31.5 vs 15.0个月,P=0.04)。

要点

  • 切除患者中位生存30.0个月,未切除者16.5个月(P<0.00001)。
  • CA19.9缓解(下降>50%)者切除后中位生存31.5个月,无缓解者15.0个月(P=0.04)。
  • 多因素分析显示KPS、T3-T4、切除和CA19.9缓解为独立预后因素。

核心结论

  • CA19.9缓解可能有助于更好地筛选初治化疗后能从切除中获益的交界可切除或局部晚期胰腺腺癌患者。

研究设计与样本

  • 回顾性研究,2002–2016年纳入223例交界可切除或局部晚期胰腺腺癌患者,接受吉西他滨联合方案(四药联合或白蛋白紫杉醇-吉西他滨)初治化疗3–6个月,后续手术和/或放化疗。

主要发现

  • 全组中位生存18.3个月;切除61例中位生存30.0个月,未切除162例中位生存16.5个月(P<0.00001)。
  • 影像学疗效:部分缓解48%,疾病稳定47%,疾病进展5%;CA19.9缓解(下降>50%)见于77.8%患者。
  • 切除患者中,CA19.9无缓解者中位生存15.0个月,缓解者31.5个月(P=0.04);无缓解切除者与未切除无缓解者中位生存10.9个月相比无显著差异(P=0.25)。
  • 多因素分析显示KPS、T3-T4状态、切除和CA19.9缓解为独立预后因素;影像学缓解、交界可切除/局部晚期区分和基线CA19.9对生存无显著影响。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with borderline (BL) or locally advanced (LA) pancreatic adenocarcinoma are usually treated with primary chemotherapy (CT), followed by resection when feasible. Scanty data are available about the criteria to candidate patients to resection after CT. PATIENTS AND METHODS: Between 2002 and 2016 overall 223 patients diagnosed with BL or LA pancreatic adenocarcinoma were primarily treated with Gemcitabine combination (4-drugs or nab-paclitaxel-gemcitabine) for 3-6 months followed by surgery and/or chemoradiation. Resection was carried out when radical resection could be predicted by imaging studies and intraoperative findings. The prognostic value of both pre-treatment factors and treatment response was retrospectively evaluated, searching for criteria that could improve the selection of patients for surgery. RESULTS: Median survival (MS) for the whole population was 18.3 months. Surgical resection was carried out in 61 patients; MS in resected patients was significantly longer (30.0 months) as compared with 162 non-resected patients (16.5 months) (P < 0.00001). According to response criteria, 48% had a radiological partial response, 47% a stable disease and 5% a disease progression); CA19.9 response (reduction >50%) was obtained in 77.8% of patients. Among resected patients, neither pre-treatment factors, including BL/LA distinction, nor radiological response, were able to prognosticate survival differences. Survival of resected patients having no CA19.9 response was significantly lower as compared with responders (MS 15.0 versus 31.5 months, P = 0.04), and was similar to non-responders patients that did not undergo resection (MS 10.9 months, P= 0.25). Multivariate analysis carried out on the overall population, showed that Karnofsky performance status, T3-T4 status, resection and CA19.9 response were independent prognostic factors, while radiological response, BL/LA distinction and baseline CA19.9 had not significant influence on survival. CONCLUSIONS: CA19.9 response may allow a better selection of patients who will benefit from resection after primary CT for BL or LA pancreatic adenocarcinoma.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Reni M, Zanon S, Balzano G, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017. PMID: 28945895. doi:10.1093/annonc/mdx495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。